Lopes-Ramos Camila M, Quackenbush John, DeMeo Dawn L
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.
Front Oncol. 2020 Nov 23;10:597788. doi: 10.3389/fonc.2020.597788. eCollection 2020.
Despite their known importance in clinical medicine, differences based on sex and gender are among the least studied factors affecting cancer susceptibility, progression, survival, and therapeutic response. In particular, the molecular mechanisms driving sex differences are poorly understood and so most approaches to precision medicine use mutational or other genomic data to assign therapy without considering how the sex of the individual might influence therapeutic efficacy. The mandate by the National Institutes of Health that research studies include sex as a biological variable has begun to expand our understanding on its importance. Sex differences in cancer may arise due to a combination of environmental, genetic, and epigenetic factors, as well as differences in gene regulation, and expression. Extensive sex differences occur genome-wide, and ultimately influence cancer biology and outcomes. In this review, we summarize the current state of knowledge about sex-specific genetic and genome-wide influences in cancer, describe how differences in response to environmental exposures and genetic and epigenetic alterations alter the trajectory of the disease, and provide insights into the importance of integrative analyses in understanding the interplay of sex and genomics in cancer. In particular, we will explore some of the emerging analytical approaches, such as the use of network methods, that are providing a deeper understanding of the drivers of differences based on sex and gender. Better understanding these complex factors and their interactions will improve cancer prevention, treatment, and outcomes for all individuals.
尽管性别差异在临床医学中的重要性已为人所知,但在影响癌症易感性、进展、生存及治疗反应的诸多因素中,基于性别和性别的差异是研究最少的因素之一。尤其是,驱动性别差异的分子机制尚不清楚,因此大多数精准医学方法在分配治疗方案时使用突变或其他基因组数据,而不考虑个体性别可能如何影响治疗效果。美国国立卫生研究院要求研究将性别作为一个生物学变量纳入考量,这已开始拓宽我们对其重要性的理解。癌症中的性别差异可能源于环境、遗传和表观遗传因素的综合作用,以及基因调控和表达的差异。全基因组范围内存在广泛的性别差异,最终影响癌症生物学特性和预后。在本综述中,我们总结了目前关于癌症中性别特异性遗传和全基因组影响的知识现状,描述了对环境暴露、遗传和表观遗传改变的反应差异如何改变疾病进程,并深入探讨了综合分析在理解癌症中性别与基因组相互作用方面的重要性。特别是,我们将探讨一些新兴的分析方法,如使用网络方法,这些方法能让我们更深入地了解基于性别和性别的差异驱动因素。更好地理解这些复杂因素及其相互作用将改善所有个体的癌症预防、治疗及预后。